News Sentiment

BMRN sentiment intelligence

Biomarin Pharmaceutical Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 59.59 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

73/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+0.8% over one week, +9.0% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Biomarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Report - Results, Call & Slides

Market Reaction

Balanced read

54/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 73/100 classification
One-week reaction 0.8% Price digesting
Trend fit Trend inactive 9.0% over four weeks
Fair value -15.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 36
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
TradingView 9
simplywall.st 7
PR Newswire 5
Stock Titan 3
ChartMill 3
Ad-hoc-news.de 2
Stock Traders Daily 2

Event Lens

What the news is about

Classified themes
Earnings 22
Market update 22
Analyst action 8
Deals and strategy 3
Regulatory and legal 3
Guidance 3
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 63
Ad-hoc-news.de Direct company coverage

BioMarin stock trades steady as rare disease revenue grows and gene therapy outlook develops

BioMarin Pharmaceutical Inc. (BMRN) stock remains steady as the company demonstrates growth in its rare disease revenue while actively developing gene therapy assets. The biotech firm's strategy involves substantial R&D investments in gene therapy programs, particularly for hemop

Tone
Positive 71/100
Event
Earnings
Published
21 Jul 2026 11:41
Source
Ad-hoc-news.de
TradingView Direct company coverage

BMRN5187965 Bond Profile — Key Metrics

This article provides a detailed profile of the BioMarin Pharmaceutical Inc. 1.25% 15-MAY-2027 bond (BMRN5187965 FINRA). It lists key metrics such as issuer, issue date, maturity date, outstanding amount, face value, minimum denomination, and coupon rate. The profile also include

Tone
Neutral 50/100
Event
Market update
Published
20 Jul 2026 11:11
Source
TradingView
Stock Traders Daily Direct company coverage

Trading Systems Reacting to (BMRN) Volatility

This article analyzes Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) volatility, identifying a neutral near-term sentiment with a mid-channel oscillation pattern. It highlights an exceptional short setup with a 25.3:1 risk-reward ratio and outlines three AI-generated trading strateg

Tone
Negative 39/100
Event
Market update
Published
17 Jul 2026 13:11
Source
Stock Traders Daily
Market source Direct company coverage

2 Reasons to Avoid BMRN and 1 Stock to Buy Instead

BioMarin Pharmaceutical (BMRN) is not recommended due to its stagnant adjusted operating margin and mediocre return on invested capital over the last five years. Despite a reasonable forward P/E, its shaky fundamentals present too much downside risk. The article suggests investin

Tone
Negative 29/100
Event
Earnings
Published
17 Jul 2026 11:45
Source
Market source
TradingView Direct company coverage

BMRN6299744 Bond Risk Profile

This article provides a risk profile for the BioMarin Pharmaceutical Inc. 5.5% 15-FEB-2034 corporate bond, identified as BMRN6299744. It outlines key metrics for credit risk assessment, including security level and issuer rating. The offering also suggests access to exclusive ana

Tone
Neutral 50/100
Event
Analyst action
Published
15 Jul 2026 15:09
Source
TradingView
TradingView Direct company coverage

BMRN6299744 Bond Profile — Key Metrics

This article provides a detailed profile of the BioMarin Pharmaceutical Inc. bond, BMRN6299744, highlighting its key metrics. It includes information such as the issuer, issue and maturity dates, outstanding amount, face value, minimum denomination, and coupon rate. The bond is a

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 14:41
Source
TradingView
Investing.com Direct company coverage

H.C. Wainwright reiterates BioMarin stock rating at Neutral

H.C. Wainwright has reiterated its Neutral stock rating and $50 price target for BioMarin Pharmaceutical Inc., despite the company trading above this target. BioMarin recently announced that the FDA accepted its supplemental New Drug Application for the full approval of VOXZOGO f

Tone
Neutral 50/100
Event
Analyst action
Published
15 Jul 2026 04:11
Source
Investing.com
Investing.com Nigeria Direct company coverage

FDA accepts BioMarin application for full VOXZOGO approval By Investing.com

The FDA has accepted BioMarin Pharmaceutical Inc.'s supplemental New Drug Application for full approval of VOXZOGO for children with achondroplasia, setting a target action date of February 28, 2027. This application is supported by extensive long-term safety and efficacy data, a

Tone
Positive 73/100
Event
Analyst action
Published
14 Jul 2026 14:14
Source
Investing.com Nigeria
Investing.com Australia Direct company coverage

H.C. Wainwright reiterates BioMarin stock rating at Neutral By Investing.com

H.C. Wainwright has reiterated a Neutral stock rating for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with a $50.00 price target. This comes after the FDA accepted BioMarin's supplemental New Drug Application for VOXZOGO for full approval in children with achondroplasia, with a ta

Tone
Positive 64/100
Event
Analyst action
Published
14 Jul 2026 12:13
Source
Investing.com Australia
Stock Titan Direct company coverage

BioMarin (BMRN) details Amicus 2025 results and $14.50-per-share merger terms

BioMarin Pharmaceutical Inc. (BMRN) filed an amendment to its acquisition report, detailing Amicus Therapeutics' 2025 financial results and pro forma financials for their merger. The amendment revealed Amicus' 2025 net product sales of $634.2 million and a net loss of $27.1 milli

Tone
Positive 67/100
Event
Deals and strategy
Published
13 Jul 2026 20:10
Source
Stock Titan
Investing.com Direct company coverage

FDA accepts BioMarin application for full VOXZOGO approval

The FDA has accepted BioMarin Pharmaceutical Inc.'s supplemental New Drug Application for full approval of VOXZOGO (vosoritide), used for children with achondroplasia. The target action date is February 28, 2027. This application is supported by extensive long-term safety and eff

Tone
Positive 71/100
Event
Analyst action
Published
13 Jul 2026 14:41
Source
Investing.com
Intellectia AI Direct company coverage

BioMarin Seeks Full Approval for VOXZOGO in Achondroplasia

BioMarin has announced that the FDA accepted its supplemental New Drug Application (sNDA) for VOXZOGO, targeting full approval for achondroplasia by February 28, 2027. This application is supported by extensive long-term safety and efficacy data from three ongoing studies, demons

Tone
Positive 65/100
Event
Regulatory and legal
Published
13 Jul 2026 14:10
Source
Intellectia AI
grafa.com Direct company coverage

BioMarin seeks full approval for VOXZOGO

BioMarin Pharmaceutical's supplemental application for full FDA approval of VOXZOGO, a therapy for achondroplasia, has been accepted. The FDA has set a target action date of February 28, 2027, to review the submission, which includes long-term safety and efficacy data from ongoin

Tone
Positive 82/100
Event
Analyst action
Published
13 Jul 2026 13:38
Source
grafa.com
PR Newswire Direct company coverage

U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia

BioMarin Pharmaceutical Inc. announced that the U.S. FDA has accepted its supplemental New Drug Application (sNDA) for VOXZOGO® (vosoritide) for full approval in children with achondroplasia. The application is supported by extensive long-term safety and efficacy data, including

Tone
Positive 72/100
Event
Regulatory and legal
Published
13 Jul 2026 13:05
Source
PR Newswire
Fierce Pharma Direct company coverage

Young people with PKU take the mic in BioMarin podcast series

BioMarin Pharmaceutical is launching a new video podcast series and TikTok campaign called "Why Do I Pheel This Way?" to raise awareness for phenylketonuria (PKU). Hosted by two young individuals with PKU, Connor and Londyn, the series explores their daily experiences with the ra

Tone
Positive 64/100
Event
Market update
Published
11 Jul 2026 01:10
Source
Fierce Pharma
Sahm Direct company coverage

Is BioMarin Pharmaceutical (BMRN) Still Below Fair Value After Its Russell Index Additions?

BioMarin Pharmaceutical (BMRN) was recently added to several Russell indexes, influencing its institutional investor perception. Despite a 5.47% 7-day and 6.31% 30-day share price return, its 3-year total shareholder return is down 29.21%. The company is considered 31.3% underval

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 13:42
Source
Sahm
DirectorsTalk Interviews Direct company coverage

BioMarin Pharmaceutical Inc. (BMRN): Investor Outlook Reveals 48.92% Potential Upside

BioMarin Pharmaceutical Inc. (BMRN), a biotechnology company specializing in rare disease therapies, shows a potential upside of 48.92% according to analyst ratings. With a market cap of $11.4 billion and a strong product pipeline including VIMIZIM and VOXZOGO, the company mainta

Tone
Positive 90/100
Event
Guidance
Published
07 Jul 2026 00:13
Source
DirectorsTalk Interviews
Finviz Direct company coverage

BMRN - Biomarin Pharmaceutical Inc Options

This article provides comprehensive financial data for BioMarin Pharmaceutical Inc. (BMRN), including its last close price, market capitalization, income, sales, and various financial ratios. It also details insider ownership, institutional ownership, profitability margins, and s

Tone
Positive 64/100
Event
Market update
Published
03 Jul 2026 21:40
Source
Finviz
Finviz Direct company coverage

BMRN - Biomarin Pharmaceutical Inc Volatility & Greeks

This article provides a detailed financial overview of BioMarin Pharmaceutical Inc. (BMRN), including its stock performance, key financial metrics, insider and institutional ownership, and various ratios. It covers aspects from market capitalization and earnings per share to vola

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 17:13
Source
Finviz
Sahm Direct company coverage

BioMarin Pharmaceutical (BMRN) Highlights ENDO 2026 Progress, Is The Stock Undervalued?

BioMarin Pharmaceutical (BMRN) is under analysis after presenting new VOXZOGO and BMN 333 data at ENDO 2026 and releasing mixed quarterly results with updated guidance. The stock shows short-term momentum but is still down over a three-year period. Despite trading at a discount t

Tone
Positive 70/100
Event
Earnings
Published
28 Jun 2026 21:40
Source
Sahm